Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
13739-02-1
Molecular formula
C19H12O8
Molecular weight
368.29 g/mol
Drug class
Anthraquinone derivativesymptomatic slow-acting medicine for osteoarthritis (SYSADOA)
Mechanism of action
Inhibits interleukin-1 beta activity and related inflammatory/catabolic pathways involved in cartilage degradation. It is a slow-acting agent and its clinical benefit may take several weeks to appear.
Indications / reported uses
Symptomatic treatment of osteoarthritis of the hip or knee only, where authorised; not recommended for rapidly progressive hip OA. EMA restrictions: do not use in patients aged 65 years or older or in those with current or previous liver disease; stop treatment if diarrhoea occurs and monitor for hepatic injury.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Diacerein Environmental Risk Assessment (ERA) (the Diacerein ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.